Drugs in MeSH Category Adrenergic beta-1 Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	NEBIVOLOL HYDROCHLORIDE	nebivolol hydrochloride	TABLET;ORAL	203825-001	Nov 3, 2020	AB	RX	No	No
Allergan	BYSTOLIC	nebivolol hydrochloride	TABLET;ORAL	021742-003	Dec 17, 2007	AB	RX	Yes	No
Allergan	BYSTOLIC	nebivolol hydrochloride	TABLET;ORAL	021742-005	Oct 8, 2008	AB	RX	Yes	Yes

Last updated: August 1, 2026

Market dynamics and patent landscape for beta-1 adrenergic receptor agonists (MeSH: Adrenergic beta-1 Receptor Agonists)

Executive summary: Beta-1 adrenergic receptor agonists sit in two commercial clusters: (1) cardiac inotropes and (2) bronchodilator-adjacent beta agonists where beta-1 selectivity is partial or formulation-driven. Patent risk is dominated by method-of-use, formulation, and delivery system patents rather than core active-ingredient protection in most jurisdictions. In practice, the forward map for market entry depends on (a) whether the branded product has active Orange Book listings (small molecules) and (b) whether biologic-like regulatory exclusivities do not apply (most of these drugs are small molecules). Where core composition patents have expired, new entrants typically face fewer composition barriers but still confront controlled-use and device/formulation IP.

The beta-1 category is not a single drug. Coverage and exclusivity differ materially across agents including dobutamine, dopamine, epinephrine (adrenaline; mixed agonist), and cardioselective beta-agonists used for specific indications and settings. The market dynamics therefore track: route of administration (IV infusions vs inhaled vs oral), indication (acute decompensated heart failure, shock, perioperative inotropy), and regulatory status (hospital-only use and tendering vs outpatient).

---

Which beta-1 adrenergic receptor agonists are the main products in the MeSH class?

Featured snippet answer: The MeSH class “Adrenergic beta-1 Receptor Agonists” maps to multiple therapeutics, with commercial and patent activity concentrated in older, generic-dominant inotropes (notably dobutamine and dopamine) and mixed agonists used for acute cardiovascular indications (notably epinephrine). Patent estates for these compounds are often limited to formulation and method-of-use after composition expiry.

Core agents that drive market supply

Most market supply for beta-1 adrenergic agonists comes from a small set of long-established molecules used primarily in acute care:

• Dobutamine (IV inotrope; beta-1 selective with some beta-2 activity)
• Dopamine (dose-dependent agonism across receptor classes)
• Epinephrine (adrenaline) (mixed alpha and beta agonist; beta-1 effects among others)

Other beta-1–leaning agents exist in niche or non-US contexts, but the primary patent and market dynamics for the MeSH bucket in regulated markets follow the above acute-care inotropes.

---

How does market demand for beta-1 agonists change across hospital vs outpatient settings?

Featured snippet answer: Demand is largely hospital-driven for acute inotropes, making tender cycles, drug shortages, and GPO contracts more important than outpatient payer formulary behavior. Outpatient demand is limited for pure beta-1 agonists because classic beta-agonist strategies for chronic disease use beta-2–oriented or mixed profiles.

Hospital dynamics that influence pricing

Key variables shaping the commercial value of beta-1 agonists:

• Tendering and procurement: municipal and national procurement systems often compress pricing quickly after generic entry.
• Inventory risk and shortages: IV products are sensitive to manufacturing disruptions, which can temporarily increase realized pricing even when the legal exclusivity has expired.
• Formulary standardization: hospitals standardize to a small number of SKUs by concentration and packaging, which creates room for formulation/device IP even after active ingredient patents end.

Outpatient dynamics (limited relevance)

If outpatient use exists, it is usually secondary to product availability rather than sustained chronic prescribing, which keeps the patent value of extended-release or inhalation delivery concepts relatively lower for this MeSH class.

---

What patents protect dobutamine, dopamine, and epinephrine in the US and Europe?

Featured snippet answer: For older beta-1 agonists, core composition patents often expired years ago. The remaining protection typically comes from:

1. formulation patents (concentration, stabilizers, pH, buffers),
2. packaging patents (container closure systems, prefilled syringes),
3. method-of-use patents tied to specific indications, infusion parameters, or protocols, and
4. manufacturing process patents (purification steps, crystallization, sterile filtration strategy).

US patent landscape patterns (small molecules)

Typical US residual estates:

• Formulation and stability claims that survive composition expiry because generics avoid exact matches while still needing therapeutic equivalence.
• Method-of-use claims that can drive settlement leverage in ANDA/505(b)(2) disputes, especially where dosing protocols differ.
• Device or delivery system protection where the product is prefilled or requires specific administration workflows.

Europe and “SPC gravity”

In Europe, effective exclusivity is often extended by Supplementary Protection Certificates (SPCs) where eligible. For older actives, many SPC windows have already run. Where SPCs did exist, the downstream patent estate tends to focus on:

• formulation improvements,
• use in specific subpopulations (where supported by data),
• and manufacturing/process improvements.

---

When does exclusivity end for beta-1 agonists, and what triggers generic launch timing?

Featured snippet answer: For most established beta-1 agonists, market exclusivity has moved to generic availability. Launch timing is now triggered by patent expiry plus any exclusivity still listed in regulatory databases, not by biologic-style exclusivity.

Timing drivers in US

For small-molecule products, generic launch can be blocked by:

• active listed patents in the FDA Orange Book (composition, method, formulation, or dosing regimen claims),
• unexpired exclusivity attached to the NDA/Numeric reference product (if still present, which is uncommon for older injectables),
• and any litigated patents under the Hatch-Waxman framework (Paragraph IV).

In practice, hospital injectables often have multiple listed patents, which prolong the settlement window even after composition expiry.

Timing drivers outside US

In EU:

• patent expiry and any SPC expiry govern the composition and use windows,
• national court outcomes drive enforcement,
• parallel import rules and tendering affect when a competitor product meaningfully replaces a branded incumbent.

---

What is the Orange Book status of beta-1 agonist products?

Featured snippet answer: Orange Book status depends on the specific NDA and listed patents for each formulation and route. For the MeSH class as a group, the pattern is mixed: older injectables typically have Orange Book listings long past main exclusivity, with remaining patents concentrated in formulation or method-of-use.

How Orange Book listings shape litigation posture

Orange Book listing density affects:

• the number of potential Paragraph IV targets,
• the expected duration of settlement negotiations,
• and the likelihood that generics take a “carve-out” position (labeling differences or narrow claim design-around).

---

How many patents cover each beta-1 agonist formulation, and what claim types dominate?

Featured snippet answer: Patent coverage density is typically highest for branded IV products because manufacturers file multiple layers:

• composition (often expired),
• formulation and stability (often active historically, now variably),
• and method-of-use tied to dosing or clinical protocols.

In many cases, claim type dominance shifts over time:

• early years: composition,
• mid-life: formulation and process,
• later: device/packaging and protocol-based method-of-use.

Claim-type map that guides freedom-to-operate

For beta-1 agonists, FTO assessments typically segment patents into:

• formulation (pH range, stabilizers, osmolarity targets),
• manufacturing (sterile filtration and sterilization validation steps),
• administration (infusion rates, mixing instructions, compatibility with co-administered fluids),
• indication (specific acute care settings, subtypes of shock, perioperative cardiac support).

---

What patent litigation and Paragraph IV challenges affect beta-1 agonists?

Featured snippet answer: Litigation for older beta-1 agonists usually centers on:

• whether generics induce infringement through equivalent dosing or administration methods,
• whether the generic formulation infringes stability/pH claim ranges,
• and whether the label can avoid method-of-use claims.

Typical settlement architecture

Common outcomes include:

• “design-around” where the generic changes formulation elements or avoids labeling language,
• partial dismissal of asserted claims,
• and staged launch on a fraction of SKUs (different concentrations, containers, or packaging configurations).

---

What formulations are protected by the remaining patents for beta-1 agonists?

Featured snippet answer: For injectable beta-1 agonists, the most durable formulation IP relates to stability and compatibility:

• stabilizer systems and antioxidants,
• buffer and pH targets that maintain potency,
• and sterile handling characteristics compatible with pharmacy compounding practices.

Concentration and packaging as patent leverage

Branded injectables often have multiple strengths. Patent claims may cover:

• specific concentration ranges,
• specific container closure systems (prefilled syringe vs vial),
• and administration-ready formats that hospitals use to reduce compounding errors.

---

Do method-of-use patents for beta-1 agonists extend exclusivity beyond composition expiry?

Featured snippet answer: Yes, when method-of-use claims are still active and still listed or otherwise enforceable. These claims can extend commercial protection by forcing generics to avoid certain protocols or dosing instructions, which affects product launch readiness and labeling.

Method-of-use claim themes

• infusion strategy tied to hemodynamic endpoints,
• dosing adjustments by patient subtypes,
• use in acute settings (shock phenotypes, perioperative support),
• and co-administration compatibility (where claimed).

---

How does biosimilar risk apply to beta-1 adrenergic receptor agonists?

Featured snippet answer: Biosimilar risk is largely not applicable because beta-1 adrenergic receptor agonists in this MeSH class are not biologics. Competitive risk comes from generics, not biosimilars.

---

Which companies compete for beta-1 agonist supply, and how does patent status affect their entry?

Featured snippet answer: Competition is driven primarily by generic manufacturers and sterile injectable specialists. Branded incumbents retain advantage only where residual formulation/device or method-of-use IP persists and where hospitals standardize on the incumbent’s SKU.

Competitive pattern by product type

• Vials: faster generic replacement after patent expiry because formulation equivalence is easier.
• Prefilled formats: slower replacement where container closure and administration workflow are patented.
• Multiple concentrations: generics may launch in the most-used strengths first and later expand to other strengths.

---

How does beta-1 agonist patent estate strength compare with other adrenergic MeSH classes?

Featured snippet answer: Patent estate strength tends to be weaker than newer adrenergic drug classes because beta-1 agonists in this bucket are older and typically face earlier composition expiry. Remaining value is concentrated in formulation, packaging, and protocol-based method-of-use rather than new molecular entities.

Relative risk profile

• Higher composition certainty of generic entry for older injectables.
• Higher litigation and design-around activity for method-of-use and formulation claims that are more label- and protocol-sensitive.

---

Revenue exposure: which beta-1 agonist SKUs represent the biggest IP-driven cash flows?

Featured snippet answer: The highest revenue exposure typically concentrates in:

• widely used IV inotropes with standardized hospital purchasing,
• branded products with multiple strengths and packaging configurations,
• and products where pharmacies rely on branded administration-ready formats.

Where IP drives revenue longest

• delivery system and packaging patents that reduce hospital compounding friction,
• and method-of-use claims that constrain generic labeling.

---

Key scenarios for generic entry risks in beta-1 adrenergic agonists

Featured snippet answer: Generic entry risk is elevated where patents still list formulation stability ranges or method-of-use dosing protocols that the generic must mirror for therapeutic equivalence and label acceptance.

Scenario map

• Low risk: composition expired; no active formulation/method patents listed for the specific strength/container.
• Medium risk: formulation patents active but solvable via excipient and pH-range design-around; labeling work may be required.
• High risk: method-of-use claims still enforceable and listed; design-around forces label changes that may reduce commercial viability.

---

Cross-jurisdiction enforcement: do US and EU patent outcomes diverge for beta-1 agonists?

Featured snippet answer: Outcomes can diverge because claim scope and enforceability standards differ between the US and EU. Even when composition protection expires globally, EU SPC validity and national enforcement can preserve a pocket of exclusivity for certain formulations or uses.

Commercial effect of divergence

• US generics may launch with design-around while EU entry waits for national injunction posture or SPC-related resolution.
• Tendering in EU can lag behind US competitive normalization.

---

Key takeaways

• Beta-1 adrenergic agonists in this MeSH class are dominated by older, generic-dominant injectables, with the remaining patent value concentrated in formulation, packaging/device, and method-of-use protocol claims rather than core composition.
• Patent-driven market dynamics are now defined by Orange Book listing density (US) and, where applicable, SPC and national enforcement posture (EU).
• Generic launch timing is most sensitive to method-of-use and stability/formulation claim scope, which affects labeling readiness and tender acceptance.
• Biosimilar pathways are not a meaningful threat vector for this MeSH class; the competitive battleground is ANDA-style generic entry and associated litigation/design-around.

---

FAQs

1. What patent claim types most commonly survive against ANDA filers for injectable beta-1 agonists?
2. How do hospital tender cycles change the practical impact of patent expiry dates for IV inotropes?
3. What is the most common design-around strategy for formulation-stability patents on beta-1 agonist injectables?
4. Do method-of-use claims for acute hemodynamic indications materially delay generic launch for beta-1 agonists?
5. How often do US Orange Book-listed patents differ in scope from EU patent claims for the same beta-1 agonist product?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. U.S. Patent and Trademark Office. Patent Term and Adjustments; general principles (context for expiration and exclusivity timelines). USPTO.
3. European Medicines Agency (EMA). Supplementary Protection Certificates (SPC) guidance and regulatory framework. EMA.